Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$2.31 - $4.99 $9,240 - $19,960
4,000 Added 400.0%
5,000 $17,000
Q1 2022

May 09, 2022

BUY
$14.73 - $35.25 $7,365 - $17,625
500 Added 100.0%
1,000 $20,000
Q2 2021

Aug 11, 2021

BUY
$56.91 - $127.53 $28,455 - $63,765
500 New
500 $37,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $538M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Banque Cantonale Vaudoise Portfolio

Follow Banque Cantonale Vaudoise and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Cantonale Vaudoise, based on Form 13F filings with the SEC.

News

Stay updated on Banque Cantonale Vaudoise with notifications on news.